Pernio

Back

Background

Pernio is an inflammatory skin condition presenting after exposure to cold as pruritic and/or painful erythematous-to-violaceous acral lesions. Pernio may be idiopathic or secondary to an underlying disease. Note the image below.



View Image

A 63-year-old man with pernio presenting as acral violaceous plaques with bullae.

Pathophysiology

Pernio is due to an abnormal vascular response to cold exposure,[1] and it is most frequent when damp or humid conditions coincide. Minor trauma also may predispose the acral parts to symptomatic pernio lesions in otherwise appropriate weather conditions. Hyperhidrosis and low lody mass index are suggested associations.[2] The response of pernio to vasodilator drugs varies. Keeping acral areas warm and dry best prevents pernio.

Etiology

The direct cause of pernio is cold exposure; specifically, exposure to both mild nonfreezing cold and humidity seems to be required.[3, 4] Chronic pernio may be secondary to various systemic diseases as follows:

Variants include the following:

Epidemiology

Frequency

United States

The true incidence of pernio is unknown because pernio frequently is unrecognized or misdiagnosed.

International

Rates of pernio vary with climate. England, with its cool damp climate, has an annual incidence rate of pernio of 10%. A clustering of pernio cases has been reported from Hong Kong during January and February, with resolution of most cases within a few weeks when the weather warmed.[13]

Sex

Women are affected by pernio more frequently than men.

Age

Pernio is most frequent in young and middle-aged women and in children. Note the image below.



View Image

Erythematous macules on distal toes of a 6-month-old girl with pernio.

Prognosis

Prognosis is good. Recurrences may be observed annually with onset of cold weather.[7] Long-term follow-up of patients with chronic recurrent pernio is advised because this may reveal connective-tissue disease (lupus erythematosus). Most cases of pernio resolve without any adverse reactions.

Patient Education

Avoid exposure to cold.

Keep extremities warm and dry.

Cease smoking.

History

Most patients with pernio present with a history of recurrent painful and/or pruritic, erythematous, violaceous papules or nodules on the fingers and/or toes. Most cases of pernio resolve within 2-3 weeks. Elicit a history of cold exposure or repeated episodes of cold exposure.

Physical Examination

Pertinent findings in pernio are limited to the skin. Cutaneous pernio lesions present 12-24 hours after cold exposure as red or violaceous macules, papules, nodules, or plaques, which may form vesicles or ulcerate. Pernio lesions occur on acral areas, are associated with burning or pruritus, and last 1-3 weeks. Note the images below.



View Image

Close-up of erythematous macules and plaques on distal plantar toes.



View Image

Close-up of great toe bulla.

Complications

Pernio lesions that blister may become secondarily infected.

Laboratory Studies

The following laboratory tests may be needed:

Histologic Findings

Pernio can often be diagnosed on the basis of clinical findings. Biopsy may be indicated to rule out other inflammatory processes in difficult chronic cases. Punch biopsy is adequate. There is variable epidermal spongiosis or necrosis. Intense papillary dermal edema is present. A superficial and deep perivascular lymphocytic infiltrate is seen, with the described "fluffy edema" of vessel walls. Lymphocytic vasculitis may be present.

Medical Care

Prophylactic warming of acral areas, achieved by heat and appropriate clothing, best prevents pernio.

Ultraviolet light, given at the beginning of the cold, damp season, has been touted as preventing outbreaks of pernio in prone individuals. Pathogenesis was loosely based on damaging the minute vessels and minimizing their ability to vasoconstrict with subsequent cold exposure. However, in at least one double-blind study, ultraviolet therapy was of no value in prophylaxis of pernio.[14]

Avoidance of nicotine may help alleviate pernio.[4]

Consultations

Consult a dermatologist for diagnosis and evaluation of associated disease.

Diet

Thin body habitus may be associated with heightened cutaneous vasoreactivity; the healthcare provider needs to be aware of this population at risk.

Activity

Prophylactic warming of acral areas with minimization of cold exposure may prevent disease recurrence.

Prevention

Avoid exposure to cold.

Cease smoking.

Medication Summary

The use of topical and systemic steroids, vasodilators,[9, 15, 16, 17] intravenous calcium followed by intramuscular vitamin K, and ultraviolet B radiation have been anecdotally reported in the literature. In most cases of pernio, the value of these agents is at best questionable.

Nifedipine (Procardia)

Clinical Context:  Nifedipine relaxes coronary smooth muscle and produces coronary vasodilation, which, in turn, improves myocardial oxygen delivery. Small studies have shown this drug to be effective in reducing symptoms associated with severe recurrent pernio. Nifedipine is currently considered the drug of choice.

Class Summary

Peripheral arterial vasodilators may be effective in the treatment and prevention of pernio.

What is pernio?What is the pathophysiology of pernio?What causes pernio?What are variants of pernio?What is the prevalence of pernio in the US?What is the global prevalence of pernio?What are the sexual predilections of pernio?Which patient groups have the highest prevalence of pernio?What is the prognosis of pernio?What is included in patient education about pernio?Which clinical history findings are characteristic of pernio?Which physical findings are characteristic of pernio?What are the possible complications of pernio?Which conditions should be included in the differential diagnoses of pernio?What are the differential diagnoses for Pernio?What is the role of lab testing in the workup of pernio?What is the role of biopsy in the diagnosis of pernio?How is pernio treated?Which specialist consultations are beneficial to patients with pernio?What is a risk factor for heightened cutaneous vasoreactivity in patients with pernio?How is recurrence of pernio prevented?How is pernio prevented?Which medications are used in the treatment of pernio?Which medications in the drug class Calcium channel blockers are used in the treatment of Pernio?

Author

Michele S Maroon, MD, Program Director, Department of Dermatology, Geisinger Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

David Hensley, MD, Mullanax Dermatology Associates, Arlington Memorial Hospital

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Additional Contributors

Craig A Elmets, MD, Professor and Chair, Department of Dermatology, Director, Chemoprevention Program Director, Comprehensive Cancer Center, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: University of Alabama at Birmingham; University of Alabama Health Services Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ferndale Laboratories<br/>Received research grant from: NIH, Veterans Administration, California Grape Assn<br/>Received consulting fee from Astellas for review panel membership; Received salary from Massachusetts Medical Society for employment; Received salary from UpToDate for employment. for: Astellas.

References

  1. Shahi V, Wetter DA, Cappel JA, Davis MD, Spittell PC. Vasospasm Is a Consistent Finding in Pernio (Chilblains) and a Possible Clue to Pathogenesis. Dermatology. 2015 Sep. 231 (3):274-9. [View Abstract]
  2. Singh GK, Datta A, Grewal RS, Suresh MS, Vaishampayan SS. Pattern of chilblains in a high altitude region of Ladakh, India. Med J Armed Forces India. 2015 Jul. 71 (3):265-9. [View Abstract]
  3. Prakash S, Weisman MH. Idiopathic chilblains. Am J Med. 2009 Dec. 122(12):1152-5. [View Abstract]
  4. Almahameed A, Pinto DS. Pernio (chilblains). Curr Treat Options Cardiovasc Med. 2008 Apr. 10(2):128-35. [View Abstract]
  5. Kelly JW, Dowling JP. Pernio. A possible association with chronic myelomonocytic leukemia. Arch Dermatol. 1985 Aug. 121(8):1048-52. [View Abstract]
  6. White KP, Rothe MJ, Milanese A, Grant-Kels JM. Perniosis in association with anorexia nervosa. Pediatr Dermatol. 1994 Mar. 11(1):1-5. [View Abstract]
  7. Akkurt ZM, Ucmak D, Yildiz K, Yürüker SK, Celik HÖ. Chilblains in Turkey: a case-control study. An Bras Dermatol. 2014 Jan-Feb. 89 (1):44-50. [View Abstract]
  8. Rustin MH, Foreman JC, Dowd PM. Anorexia nervosa associated with acromegaloid features, onset of acrocyanosis and Raynaud's phenomenon and worsening of chilblains. J R Soc Med. 1990 Aug. 83(8):495-6. [View Abstract]
  9. Kearby R, Bowyer S, Scharrer J, Sharathkumar A. Case Report: Six-Year-old Girl With Recurrent Episodes of Blue Toes. Clin Pediatr (Phila). 2010 Jan 28. [View Abstract]
  10. Su WP, Perniciaro C, Rogers RS 3rd, White JW Jr. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis. 1994 Dec. 54(6):395-9. [View Abstract]
  11. Viguier M, Pinquier L, Cavelier-Balloy B, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore). 2001 May. 80(3):180-8. [View Abstract]
  12. Reinertsen JL. Unusual pernio-like reaction to sulindac. Arthritis Rheum. 1981 Sep. 24(9):1215. [View Abstract]
  13. Chan Y, Tang WY, Lam WY, et al. A cluster of chilblains in Hong Kong. Hong Kong Med J. 2008 Jun. 14(3):185-91. [View Abstract]
  14. Langtry JA, Diffey BL. A double-blind study of ultraviolet phototherapy in the prophylaxis of chilblains. Acta Derm Venereol. 1989. 69(4):320-2. [View Abstract]
  15. Verma P. Topical Nitroglycerine in Perniosis/Chilblains. Skinmed. 2015 May-Jun. 13 (3):176-7. [View Abstract]
  16. Dowd PM, Rustin MH, Lanigan S. Nifedipine in the treatment of chilblains. Br Med J (Clin Res Ed). 1986 Oct 11. 293(6552):923-4. [View Abstract]
  17. Rustin MH, Newton JA, Smith NP, Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol. 1989 Feb. 120(2):267-75. [View Abstract]

A 63-year-old man with pernio presenting as acral violaceous plaques with bullae.

Erythematous macules on distal toes of a 6-month-old girl with pernio.

Close-up of erythematous macules and plaques on distal plantar toes.

Close-up of great toe bulla.

Erythematous macules on distal toes of a 6-month-old girl with pernio.

Close-up of erythematous macules and plaques on distal plantar toes.

A 63-year-old man with pernio presenting as acral violaceous plaques with bullae.

Close-up of great toe bulla.